<DOC>
	<DOCNO>NCT01407068</DOCNO>
	<brief_summary>The objective study assess safety efficacy concurrent administration two injection AA4500 hand subject multiple Dupuytren 's contracture cause palpable cord .</brief_summary>
	<brief_title>Administration Two Injections Multiple Dupuytren 's Contractures</brief_title>
	<detailed_description>Methodology/Study Design : This open-label , study men woman multiple Dupuytren 's contracture . Approximately 60 subject least two Dupuytren 's contracture cause palpable cord hand enrol . After pre-injection procedure complete Day 1 , eligible men woman receive two concurrent injection AA4500 0.58 mg hand . On Day 2 , finger extension procedure facilitate cord disruption perform subject spontaneous disruption cord ( ) . Follow-up visit evaluation safety efficacy Day 8 , Day 30 , Day 60 . Upon completion Day 60 follow-up visit , subject require treatment option receive three additional open-label treatment accord XIAFLEX package insert ( Appendix C ) . Subjects may receive total five injection individual cord may receive total three injection .</detailed_description>
	<mesh_term>Contracture</mesh_term>
	<mesh_term>Dupuytren Contracture</mesh_term>
	<criteria>1 . Provide write informed consent 2 . Be man woman ≥ 18 year age 3 . Have diagnosis Dupuytren 's disease least 2 fixedflexion contracture hand ≥ 20º PIP and/or MP joint finger , thumb , cause palpable cord suitable treatment 4 . Have positive `` table top test '' define inability simultaneously place affect finger ( ) palm flat table top 5 . Either use accepted method birth control ( ie , surgical sterilization ; intra uterine contraceptive device ; oral contraceptive ; diaphragm condom combination contraceptive cream , jelly foam ) negative pregnancy test administration AA4500 , female childbearing potential , postmenopausal female ( menses least 1 year hysterectomy ) 6 . Not clinically significant medical history condition ( ) would , opinion investigator , substantially increase risk associate subject 's participation protocol compromise scientific objective study 7 . Be able comply study visit schedule specify protocol 1 . Received surgery ( fasciectomy surgical fasciotomy ) and/or needle aponeurotomy/fasciotomy select joint treat within 90 day first injection AA4500 2 . Has chronic muscular , neurological , neuromuscular disorder affect hand 3 . Has know systemic allergy collagenase excipient AA4500 4 . Has receive collagenase treatment ( eg , Santyl® ointment and/or XIAFLEX/XIAPEX ) within 30 day injection AA4500 5 . Is currently receive plan receive anticoagulant medication receive anticoagulant medication ( except ≤ 150 mg aspirin daily overthecounter nonsteroidal antiinflammatory drug [ NSAIDs ] ) within 7 day injection AA4500 ) 6 . Has know recent history stroke , bleeding , medical condition , investigator 's opinion would make subject unsuitable enrollment study 7 . Is know immunocompromised human immunodeficiency virus ( HIV ) positive 8 . Has history illicit drug abuse alcoholism within year injection AA4500 9 . Received investigational drug within 30 day injection AA4500 10 . Is pregnant lactate female 11 . Has clinically significant medical history condition ( ) , include condition affect hand , would , opinion investigator , substantially increase risk associate subject 's participation protocol compromise scientific objective study 12 . Has jewelry hand treat remove</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>